PHRM:CSE, PharmaTher Holdings Ltd.
PHRM stock overview
PharmaTher Holdings Ltd. (PHRM:CSE) closed at $0.055 on October 22, 2026,
unchanged on the day.
The stock trades 65.6% below its 52-week high of $0.160
and 22.2% above its 52-week low of $0.045.
Over the past year, it lost 52.2%.
PharmaTher Holdings Ltd. is part of the Life Sciences sector.
Key figures
- Price
- $0.055
- Day change
- 0.00%
- Volume
- 0
- Average volume
- 49,338
- Market cap
- 5M+
- 52-week range
- $0.045 – $0.160
- 50-day average
- $0.055
- 200-day average
- $0.067
Price action over the past year
In 252 trading sessions since October 23, 2025, PHRM closed higher on 51 days (20%).
Its best day was April 20, 2026 (+46.67%) and its worst was June 22, 2026 (-23.08%).
The stock moved 10% or more in a single session 29 times.
It opened at least 5% above the previous day's high 19 times.
Recent signals
PHRM news
-
Oct 7, 2026:
PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
-
Oct 5, 2026:
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
-
Oct 1, 2026:
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
-
Aug 18, 2026:
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
-
Aug 11, 2026:
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
-
Jul 29, 2026:
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
-
Jul 27, 2026:
PharmaTher Launches New Division to Commercialize Personalized Peptide Products
-
Jul 27, 2026:
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.
Similar stocks
Find more stocks like PHRM with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.